NMRA Neumora Corp: Market Value to Book Value Ratio
Neumora Therapeutics (NMRA) focuses on developing drugs for CNS pathologies, relying on internal reserves until the first profit is realized. The molecule discovery process is being accelerated through the implementation of automated biomaterial screening systems, with an efficiency rate of 1.64. The stock price action is presented below; it complements data regarding the company's commitment to environmental standards and ethics in conducting medical research.
Neumora (NMRA) - metric breakdowns and financial figures
- share price and expert price forecast:
- company stock capitalization data:
- book capitalization data:
- debt and solvency information:
Debt to Equity Neumora Therapeutics|NMRA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Neumora Therapeutics Inc|NMRA - Company Cumulative Debt|Debt to Book Capitalization Ratio Neumora Therapeutics Inc|NMRA - Company Long-Term Indebtedness|Company Short-Term Debts Neumora Therapeutics|Quick Liquidity Indicator neumoratx.com
- earnings and valuation multiples indicators:
Comprehensive company analysis:Neumora Therapeutics
This ratio measures the market premium over net assets, determining the degree to which business value deviates from its book value. By analyzing this chart of market capitalization to book assets, an investor can see market expectations regarding the data science approach of Neumora Therapeutics (NMRA) to treating depression, where a high premium reflects the potential precision of patient neural profiling.
Key competitors
BIIB: Market Capitalization to Book Value Ratio|neurocrine.com (NBIX) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited|Capitalization to Book Value Ratio AXSM (Axsome)|Market Capitalization to Book Value Ratio ACAD|XENE - Market-to-Book Ratio|Viking Therapeutics - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio supernus.com SUPN|CPRX - Market Value to Book Value Ratio|Market Value to Book Value DNLI (Denali)|Harmony Pharma (HRMY) - Market Value to Book Value Ratio|Market-to-Book Ratio Biohaven Corp (BHVN)|Market Value to Book Value Ratio Amylyx Pharmaceuticals|Capitalization to Book Value Ratio TRVI (trevitherapeutics.com)|Market Capitalization to Book Value Ratio PRAX|AVXL - Market-to-Book Ratio|CeriBell Corp - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio Prothena PRTA|ALEC - Market Value to Book Value Ratio|annexonbio.com (ANNX) - Market Cap to Net Assets Ratio|omeros.com (OMER) - Market Value to Book Value Ratio|Market-to-Book Ratio Neurogene Inc (NGNE)|Market Value to Book Value Ratio AC Immune Corp|VYGR: Market Value to Book Value|Market Capitalization to Book Value Ratio SCLX|Market Capitalization to Book Value Ratio tevogen.com (TVGN)|Alpha Cognition Inc. - Market Cap to Net Assets Ratio|Market Value to Book Value CGTX|IKT: Market Cap to Net Assets Ratio|Cassava Pharma - Market Cap to Book Value Multiple|ASRT: Market Capitalization to Book Value Ratio|Coya Therapeutics - Market Value to Book Value|VTGN (VistaGen Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Ovid Rx OVID|Market Value to Book Value Ratio Acumen Pharma (ABOS)|CRVO (CervoMed Corporation) - Market Value to Book Value|Market Capitalization to Book Value Ratio ATHE (Alterity Therapeutics Limited)|Market Capitalization to Book Value Ratio Clene Inc CLNN|PEPG - Market Value to Book Value Ratio|Market Capitalization to Net Assets JUNS|RLMD: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Annovis Bio Corporation (ANVS)|Market Cap to Net Assets Ratio GRCE|Market Capitalization to Book Value Ratio fireflyneuro.com|Market Cap to Net Assets Ratio KLTO (Klotho Neurosciences Inc)|Market Cap to Book Value Multiple NRSN|Market Capitalization to Book Value Ratio RVPH (Reviva Pharmaceuticals Holdings)|Market Capitalization to Book Value MetaVia Inc. (MTVA)|NeurAxis, Inc. - Market Capitalization to Book Value Ratio|Helius Medical (HSDT) - Market Cap to Net Assets Ratio|passagebio.com (PASG) - Market Value to Book Value Ratio|NEUP - Market Capitalization to Book Value|Market Value to Book Value Ratio Minerva Neurosciences Corp|Capitalization to Book Value Ratio ATHA (Athira Pharma Corp)|Market Value to Book Value Ratio Addex Therapeutics (ADXN)|Market Cap to Net Assets Ratio alzamend.com ALZN|Market Value to Book Value Ratio Cyclerion Therapeutics, Inc. CYCN|Market Value to Book Value PTIX|Pasithea - Market Capitalization to Book Value Ratio|CRGT - Market Capitalization to Book Value Ratio|Avenue Therapeutics (ATXI) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio BCLI|CARA (Cara Therapeutics) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Chromocell Therapeutics Corp CHRO|Market Cap to Net Assets Ratio ELYM (Eliem Therapeutics)|Market Capitalization to Book Value Ratio intracellulartherapies.com (ITCI)|Market Value to Book Value Ratio Longboard Pharmaceuticals LBPH|Market Value to Book Value MRNS|NKGN - Market Value to Book Value Ratio|Market-to-Book Ratio NeuroBo Pharmaceuticals Inc|Sage Therapeutics, Inc (SAGE) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio SNPX|TRVN (Trevena, Inc.) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Vigil Neuro VIGL|Market Cap to Net Assets Ratio WENA (Anew Medical, Inc.)|Market Capitalization to Book Value Ratio Cerevel Therapeutics Inc (CERE)